 |
|
One secret to how TB sticks with you
July 10, 2009Mycobacterium tuberculosis is arguably the world's most successful infectious agent because it knows how to avoid elimination by slowing its own growth to a crawl. Now, a report in the July 10 issue of the journal Cell, a Cell Press publication, offers new insight into the bugs' talent for meager living.
"Tuberculosis can resist the host immune system and remain latent for decades," said Michael Glickman of the Memorial Sloan-Kettering Cancer Center. To do so, the mycobacterium responsible must resist an arsenal of DNA-damaging mutagens produced within the macrophage, the immune cell in which it lives. "It's incompletely understood how it can do that. We've identified one such mechanism."
The discovery could lead to new drugs that might eliminate strains of TB that have grown resistant to those that are currently available.
A whopping 30% of the world's population is infected with latent TB, the researchers said. In some people, the Tuberculosis bacterium will reactivate, causing an estimated 1.3 million deaths a year, according to the World Health Organization.
One secret to TB's success is a protein that the researchers call CarD, the new study shows. That protein ratchets down transcription of the genes encoding ribosomal RNA (rRNA) by directly binding RNA polymerase, the cellular machinery that transcribes DNA into RNA. rRNA is the central component of the ribosomes that serve as the cell's protein factories, and, Glickman explained, its production accounts for some 90 percent of all transcription.
"The mycobacterium tailors its translational machinery in response to stress within the host and we have identified CarD as a critical mediator of this response" he said.
Loss of CarD is fatal to M. tuberculosis living in cell culture, Glickman and his colleague Christina Stallings show. CarD depletion leaves the pathogen sensitive to killing by oxidative stress, starvation, and DNA damage as it fails to cut its transcription of rRNA.
Importantly, Glickman said, they were able to show in infected mice that the mycobacterium depends on CarD not just when it is in its early, most active phase of growth, but also later in the course of infection. Drugs that target CarD's interaction with RNA polymerase could therefore lead to sorely needed, new TB drugs, the researchers said.
"The TB health crisis is exacerbated by the alarming emergence of multidrug- and extensively drug-resistant strains," Glickman said. "The development of new chemotherapeutic strategies is imperative, which requires insight into the pathways involved in M. tuberculosis infection, persistence, and drug resistance. CarD is one such pathway that we plan on targeting for therapeutic development. "
The findings might also prove to be clinically important for other disease-causing microbes.
Scientists knew before how some bacteria adapted to stress by limiting rRNA transcription, Glickman said. But the new study is the first to show how this is done in a mycobacterium, which lack a key gene responsible in other bugs like E. coli.
CarD is widely distributed in the bacterial world, he said, for instance it is found in Bacillus anthracis, the bacterium that causes anthrax. "This finding may have broader application to other important pathogens," he said.
Cell Press
A whopping 30% of the world's population is infected with latent TB, the researchers said. In some people, the Tuberculosis bacterium will reactivate, causing an estimated 1.3 million deaths a year, according to the World Health Organization.
One secret to TB's success is a protein that the researchers call CarD, the new study shows. That protein ratchets down transcription of the genes encoding ribosomal RNA (rRNA) by directly binding RNA polymerase, the cellular machinery that transcribes DNA into RNA. rRNA is the central component of the ribosomes that serve as the cell's protein factories, and, Glickman explained, its production accounts for some 90 percent of all transcription.
"The mycobacterium tailors its translational machinery in response to stress within the host and we have identified CarD as a critical mediator of this response" he said.
Loss of CarD is fatal to M. tuberculosis living in cell culture, Glickman and his colleague Christina Stallings show. CarD depletion leaves the pathogen sensitive to killing by oxidative stress, starvation, and DNA damage as it fails to cut its transcription of rRNA.
Importantly, Glickman said, they were able to show in infected mice that the mycobacterium depends on CarD not just when it is in its early, most active phase of growth, but also later in the course of infection. Drugs that target CarD's interaction with RNA polymerase could therefore lead to sorely needed, new TB drugs, the researchers said.
"The TB health crisis is exacerbated by the alarming emergence of multidrug- and extensively drug-resistant strains," Glickman said. "The development of new chemotherapeutic strategies is imperative, which requires insight into the pathways involved in M. tuberculosis infection, persistence, and drug resistance. CarD is one such pathway that we plan on targeting for therapeutic development. "
The findings might also prove to be clinically important for other disease-causing microbes.
Scientists knew before how some bacteria adapted to stress by limiting rRNA transcription, Glickman said. But the new study is the first to show how this is done in a mycobacterium, which lack a key gene responsible in other bugs like E. coli.
CarD is widely distributed in the bacterial world, he said, for instance it is found in Bacillus anthracis, the bacterium that causes anthrax. "This finding may have broader application to other important pathogens," he said.
Cell Press
Tuberculosis Current Events and Tuberculosis News RSSStudy reveals why certain drug combinations backfire
Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow.
Drug industry, nonprofits join forces to fight world's neglected diseases
Drug companies and nonprofit organizations are joining forces to develop new drugs and vaccines to target so-called "neglected" diseases that claim millions of lives in the developing world each year.
U.S. and European Experts Applaud Creation of New Transatlantic Task Force on Global Antibiotic Resistance Threat
Experts on both sides of the Atlantic applaud President Barack Obama and Swedish Prime Minister Fredrik Reinfeldt, representing the European Union (EU) Presidency, for establishing a transatlantic task force to address antibiotic resistance, an urgent and growing problem that threatens patient safety and public health worldwide.
1930s drug slows tumor growth
Drugs sometimes have beneficial side effects. A glaucoma treatment causes luscious eyelashes. A blood pressure drug also aids those with a rare genetic disease.
There's a speed limit to the pace of evolution, Penn biologists say
Researchers at the University of Pennsylvania have developed a theoretical model that informs the understanding of evolution and determines how quickly an organism will evolve using a catalogue of "evolutionary speed limits."
Cell phones become handheld tools for global development
Mobile phones are on the verge of becoming powerful tools to collect data on many issues, ranging from global health to the environment.
Will genomics help prevent the next pandemic?
This week, the Public Library of Science, an open-access publisher, presents the "Genomics of Emerging Infectious Disease," a collection of essays, perspectives, and reviews that explores how genomics-with all its associated tools and techniques-can provide insights into our understanding of emerging infectious disease.
Exon-skipping drug prevents muscle wasting, maintains muscle function in dystrophin deficient mice
An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.
Scientists take step toward simple and portable tuberculosis tests for developing world
Two billion people worldwide carry the pathogen that causes tuberculosis (TB), and most of them do not even know they are infected. This is because some 90 percent of people with TB have "latent" infections. They have no symptoms, they can't spread the disease to others and the bug remains dormant in their lungs -- often for years.
High mortality rates may explain small body size
A new study suggests that high mortality rates in small-bodied people, commonly known as pygmies, may be part of the reason for their small stature.
More Tuberculosis Current Events and Tuberculosis News Articles
 |
The White Plague: Tuberculosis, Man and Society by Jean Dubos (Author) |
 |
Tuberculosis: A Comprehensive Clinical Reference by H. Simon Schaaf MBChB(Stellenbosch) MMed Paed(Stellenbosch) DCM(Stellenbosch) MD Paed(Stellenbosch) (Editor), Alimuddin I. Zumla BSc MBChB MSc PhD(Lond) FRCP(Lond) FRCP(Edin) (Editor) This book provides all the vital information you need to know about tuberculosis, especially in the face of drug-resistant strains of the disease. Coverage includes which patient populations face an elevated risk of infection, as well as which therapies are appropriate and how to correctly monitor ongoing treatment so that patients are cured. Properly administer screening tests, interpret their results, and identify manifestations of the disease, with authoritative guidance from expert clinicians from around the world. Discusses screening tests for tuberculosis so you can interpret their results and identify not only common manifestations of the disease, but also those that are comparatively rare-such as tuberculosis in pregnant women. Covers all clinical aspects of tuberculosis... |
 |
Captain of Death: The Story of Tuberculosis by Thomas M. Daniel (Author) The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public health hazard has focused much attention on this ancient disease. This book offers a comprehensive account of the disease from prehistoric times through to the present day, detailing the attempts to eradicate it completely. Its four separate sections (the spread of tuberculosis; its infectious nature; susceptibility to it; and methods of treatment) are linked through the device of presenting... |
 |
The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS (Author), JANE BUIKSTRA (Author) Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders. |
 |
Tuberculosis (TUBERCULOSIS ( ROM)) by William N Rom (Editor), Stuart M Garay (Editor) New York Univ., NY. Summarizes the current advances in tuberculosis and discusses the pathology and pathogenesis of the disease. Also covers complications and treatment options. Chapters include history and epidemiology, genomics and microbiology, host response, therapy, and prevention and control. Previous edition: c1996. DNLM: Tuberculosis--Pulmonary. |
 |
The Forgotten Plague: How the Battle Against Tuberculosis Was Won - And Lost by Frank Ryan (Author) Tuberculosis has claimed more than a billion lives worldwide. In this acclaimed book, Dr. Frank Ryan tells the remarkable story of the dedicated doctors, chemists, and bacteriologists who halted the course of this ferocious disease--until the "old enemy" found in AIDS a deadly ally to form a drug-resistant synergy. 8 pages of photos. |
 |
Handbook of Tuberculosis by Stefan H. E. Kaufmann (Editor), Paul van Helden (Editor), Eric Rubin (Editor), Warwick J. Britton (Editor) Tuberculosis (TB), a deadly airborne disease caused by the bacterium Mycobacterium tuberculosis, takes the lives of almost 2 million people each year and is considered to be the most common infectious disease in the world. However, thanks to the efforts of researchers such as the volumes’ lead editor, Dr. Stefan H. E. Kaufmann, there have been several recent advances in fighting the disease. Dr. Stefan Kaufmann, the Founding Director of the Max Planck Institute for Infection Biology in Berlin and Professor of Microbiology and Immunology at the Charité at the Humboldt University, Berlin, has published more than 600 scientific articles and currently serves as President of the European Federation of Immunological Societies and Chair of the Immunology Division of the American... |
 |
The Return of the White Plague: Global Poverty and the 'New' Tuberculosis by Matthew Gandy (Editor), Alimuddin Zumla (Editor) The dramatic increase since the 1980s in the global prevalence of tuberculosis, a disease destined as recently as thirty years ago for complete eradication, is a story of medical failure. A pandemic whose geography defies simple categorization—it ranges from schools in the UK to prisons in Russia, from refugee camps in central Africa to affluent suburbs in North America—the 'new' tuberculosis is derived from a combination of different developments such as collapsing health-care services, shifting patterns of poverty and inequality, the spread of HIV, and the emergence of virulent drug-resistant strains. This collection provides an international survey of current thought on the spread and control of tuberculosis, covering historical, social, political, and medical aspects. While... |
 |
Historic Tuberculosis Films DVD: History of Pulmonary & Mycobacterium TB & Lung Disease Films Table of Contents: Tuberculosis (1955)11 minutes - This is a fun little film that shows a general history and overview of the effects of tuberculosis on our society. / On the Firing Line (1936) 20 minutes - A fantastic film that has great timeless statistics as well as footage and information about the fight against tuberculosis by the National Tuberculosis Association. / You are the Switchman (1951) 12 minutes running time - A film about noticing the warning signs of cancer and taking appropriate preventative action. You Are the Switchman was a groundbreaking video because it was released two years before the link between smoking cigarettes and cancer was officially out in the open. / City of Hope (1930s) 16 minutes - The Los Angeles Tuberculosis Sanatorium produced this film in the... |
 |
Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman (Author) For more than 150 years, until well into the twentieth century, tuberculosis was the dreaded scourge that AIDS is for us today. Based on the diaries and letters of hundreds of individuals over five generations, Living in the Shadow of Death is the first book to present an intimate and evocative portrait of what it was like for patients as well as families and communities to struggle against this dreaded disease. "Consumption", as it used to be called, is one of the oldest known diseases. But it wasn't until the beginning of the nineteenth century that it became pervasive and feared in the United States, the cause of one out of every five deaths. Consumption crossed all boundaries of geography and social class. How did people afflicted with the disease deal with their fate? How did their... |
| © 2009 BrightSurf.com |